| Literature DB >> 30407904 |
Yanli Lyu, Shikai Song, Liwei Zhou, Guoxia Bing, Qian Wang, Haoran Sun, Mingyue Chen, Junyi Hu, Mingyang Wang, Honglei Sun, Juan Pu, Zhaofei Xia, Jinhua Liu, Yipeng Sun.
Abstract
During 2012-2017, we collected throat swabs from dogs in China to characterize canine influenza virus (CIV) A(H3N2) isolates. A new antigenically and genetically distinct CIV H3N2 clade possessing mutations associated with mammalian adaptation emerged in 2016 and replaced previously circulating strains. This clade probably poses a risk for zoonotic infection.Entities:
Keywords: China; H3N2; PB2; adaptation; antigenicity; canine influenza; dogs; evolution; influenza; influenza A virus; mammalian adaptations; respiratory infections; serology; surveillance; viruses; zoonoses
Mesh:
Year: 2019 PMID: 30407904 PMCID: PMC6302592 DOI: 10.3201/eid2501.171878
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Maximum-likelihood phylogenetic tree of hemagglutinin genomic segment of H3N2 canine influenza viruses (CIVs). The phylogeny of 97 H3N2 CIVs available in public databases and the 8 hemagglutinin genomic segments sequenced in this study were inferred by using MEGA version 6 (https://www.megasoftware.net/) under the general time-reversible plus gamma distribution model with 1,000 bootstrap replicates. Avian isolates of ancestral strain (triangles) and canine isolates from South Korea (squares), Thailand (diamond), and the United States (circles) are indicated. Shading indicates isolates sequenced in this study. Scale bar indicates substitutions per nucleotide.
Possible mammalian adaptation related to amino acid substitutions in CIV H3N2, China, 2016–2017*
| Category | Virus protein, amino acid position, amino acid (frequency, %) | ||||
|---|---|---|---|---|---|
| Polymerase basic 2 |
| Hemagglutinin | |||
| 251 | 590 | 146 | 242 | ||
| CIV H3N2, 2006–2015 | K (89.19), R† (8.11), G (2.70) | G (100) | G (91.89), S (8.11) | V (100) | |
| CIV H3N2, 2016–2017 | R† (100) | S† (100) | S (100) | I (100) | |
| Influenza virus A(H3N2) in humans | R† (99.82), K (0.14), G (0.04) | S† (89.76), G (10.06), N (0.14), T (0.04), R (0.01) | S (99.57), G (0.42), F (0.01) | I (99.29), V (0.39), M (0.20), T (0.08), L (0.03), K (0.02) | |
| Influenza A(H1N1)pdm09 virus | R† (98.99), K (0.99), I (0.02) | S† (99.43), N (0.35), G (0.22) | K (99.64), N (0.23), R (0.07), E (0.06) | F (99.99), L (0.01) | |
*CIV, canine influenza virus. †Known determinant for adaptation to mammals.
Antigenic analysis of H3N2 subtype canine influenza viruses, China, 2009–2017*
| Antigenic group and virus | HI titer, by antigenic group and antiserum | |||||||
|---|---|---|---|---|---|---|---|---|
| A, 814/2009 | A, 362/2009 | B, 0110-2/2014 | B, 0118-256/2015 | B, 0120-265/2015 | C, 1228-9/2016 | C, 0512-13720/17 | C, 0527-147/2017 | |
| A | ||||||||
| 814/2009 | 1,280† | 1,280 | 1,280 | 160 | 320 | 320 | 320 | 160 |
| 1527/2009 | 640 | 1,280 | 2,560 | 320 | 160 | 320 | 320 | 320 |
| 1579/2009 | 640 | 2,560 | 1,280 | 160 | 160 | 320 | 320 | 320 |
| 362/2009 | 640 | 1,280† | 1,280 | 320 | 160 | 320 | 160 | 160 |
| B | ||||||||
| 1215-34/2012 | 160 | 640 | 1,280 | 160 | 640 | 1,280 | 640 | 1,280 |
| 0203-342/2013 | 320 | 640 | 640 | 640 | 640 | 640 | 1,280 | 320 |
| 1207-365/2013 | 320 | 640 | 1,280 | 640 | 1,280 | 640 | 1,280 | 640 |
| 0110-2/2014 | 640 | 2,560 | 1,280† | 640 | 320 | 1,280 | 640 | 640 |
| 0118-256/2015 | 320 | 640 | 1,280 | 1,280† | 640 | 640 | 320 | 320 |
| 0120-265/2015 | 640 | 640 | 1,280 | 640 | 1,280† | 640 | 320 | 640 |
| 0124-300/2015 | 320 | 1280 | 1280 | 640 | 640 | 160 | 640 | 640 |
| C | ||||||||
| 1228-9/2016 | 80 | 80 | 80 | 160 | 1,280 | 1,280† | 640 | 640 |
| 0424-102/2017 | 80 | 80 | 320 | 80 | 160 | 640 | 640 | 1,280 |
| 0512-120/2017 | 80 | 80 | 320 | 160 | 320 | 640 | 1,280 | 1,280 |
| 0512-133/2017 | 80 | 40 | 320 | 40 | 160 | 640 | 640 | 1,280 |
| 0512-137/2017 | 160 | 80 | 320 | 160 | 320 | 1,280 | 1,280† | 640 |
| 0527-148/2017 | 80 | 80 | 320 | 80 | 320 | 640 | 2,560 | 1,280 |
| 0527-146/2017 | 80 | 40 | 320 | 80 | 320 | 640 | 640 | 640 |
| 0527-147/2017 | 80 | 320 | 320 | 160 | 160 | 2,560 | 1,280 | 1,280† |
| 0601-159/2017 | 80 | 40 | 320 | 80 | 160 | 640 | 640 | 640 |
| 0610-173/2017 | 40 | 40 | 320 | 80 | 160 | 640 | 640 | 640 |
| 0721-36/2017 | 80 | 40 | 320 | 80 | 160 | 640 | 640 | 640 |
*Virus names are abbreviated as serial number and year. HI titers are the inverse of the highest dilution that inhibited hemagglutination. Cells containing moderate HI titers (160, 320) are shaded gray and high titers (>640) black. Low HI titers (40, 80) were not shaded. HI, hemagglutinin inhibition. †Homologous titers.
Figure 2Antigenic cartograph representative of hemagglutinin inhibition (HI) titers of canine influenza viruses, China, 2009–2017, showing antigenic groups A–C. Map was generated by using AntigenMap 3D (http://sysbio.cvm.msstate.edu/software/AntigenMap) and HI data shown in Table 2. One unit (cell) represents a 2-fold change in HI titer.